Devita, Hellman, and Rosenberg's Cancer

LWBK1006-17 LWW-Govindan-Review December 7, 2011 21:14

CHAPTER 17 CANCER OF THE

HEAD AND NECK

DAVID I. KUPERMAN

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 17.1. In the progressive development of squamous cell cancer of the head and

neck (SCCHN), which of the following is the latest event?

A. Loss of 9p

B. Loss of 3p

C. Loss of 17p

D. Loss of 11q

Question 17.2. Which of the following statements about the epidermal growth factor

receptor (EGFR) in SCCHN is FALSE?

A. EGFR overexpression can be equally and effectively targeted with

erlotinib or cetuximab in SCCHN.

B. Activated EGFR signaling results in cell growth and division.

C. EGFR overexpression enhances tumor angiogenesis.

D. High EGFR expression is associated with resistance to radiation ther-

apy.

Question 17.3. Which of the following are the risk factors for SCCHN?

A. Tobacco use

B. Alcohol use

C. Fanconi’s anemia

D. All of the above

Question 17.4. All of the following are characteristics of human papilloma virus (HPV)

positive SCCHN, EXCEPT:

A. Most patients are never smokers.

B. Survival outcomes are better than in patients with tobacco smoking-

associated SCCHN.

C. Chemotherapy response is unrelated to HPV status.

D. HPV causes nonkeratinizing tumors.

Corresponding Chapters inCancer: Principles & Practice of Oncology,Ninth Edition: 71 (Molecular Biology of

Head and Neck Cancers), 72 (Treatment of Head and Neck Cancer) and 73 (Rehabilitation after Treatment of Head

and Neck Cancer).

195